Genmab A (GMAB) Share-based Compensation (2023 - 2026)

Genmab A (GMAB) has reported Share-based Compensation for 4 consecutive years, with $37.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation fell 36.21% year-over-year to $37.0 million; the trailing twelve-month figure through Jun 2026 stood at $236.0 million (up 11.32% YoY), and the FY2025 full-year result was $128.0 million, up 21.9% from the prior year.
• Share-based Compensation fell to $37.0 million in Q2 2026 per GMAB's latest filing, from $49.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $92.0 million in Q3 2025 and bottomed at -$348.0 million in Q4 2023.
• Historically, Share-based Compensation has averaged $7.3 million across 4 years, with a median of $49.0 million in 2026.
• The widest YoY moves for Share-based Compensation: up 96.0% in 2026, down 36.21% in 2026.
• Over 4 years, Share-based Compensation stood at -$348.0 million in 2023, then jumped by 122.41% to $78.0 million in 2024, then increased by 17.95% to $92.0 million in 2025, then tumbled by 59.78% to $37.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $37.0 million, $49.0 million, and $92.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.